Approval · Notice of Compliance 35935 · 2025
SYNPHASIC 21 TABLETS: Notice of Compliance 35935
Issued August 29, 2025
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 35935
- Date
- August 29, 2025
- Company
- Pfizer Canada UlcKirkland, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Update to the Product Monograph as per advisement letter
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| SYNPHASIC 21 TABLETS | Not yet assigned | — |
| SYNPHASIC 28 TABLETS | Not yet assigned | — |
Medicinal ingredients
- ETHINYL ESTRADIOL 0.035 MG per TAB
- NORETHINDRONE 0.5 MG per TAB
- NORETHINDRONE 1 MG per TAB